Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment

• Published in: Clinics and research in hepatology and gastroenterology 2011-01, Vol.35 (1), p.48-54
• Main Authors: Samalin, E, Afchain, P, Thézenas, S, Abbas, F, Romano, O, Guimbaud, R, Bécouarn, Y, Desseigne, F, Edeline, J, Mitry, E, Bouché, O, Adenis, A, Aparicio, T, Dorval, E, Kramar, A, Ychou, M
• Format: Article
• Language: English
• Subjects: Adenocarcinoma - drug therapy; Adenocarcinoma - secondary; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic - administration & dosage; Antineoplastic Agents, Phytogenic - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Camptothecin - administration & dosage; Camptothecin - analogs & derivatives; Esophageal Neoplasms - drug therapy; Esophageal Neoplasms - secondary; Esophagogastric Junction; Esophagus; Female; Fluorouracil - administration & dosage; Gastroenterology and Hepatology; Gastroenterology. Liver. Pancreas. Abdomen; Humans; Internal Medicine; Male; Medical sciences; Middle Aged; Retrospective Studies; Stomach Neoplasms - drug therapy; Stomach Neoplasms - secondary; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus; Tumors
• ISSN: 2210-7401; 0399-8320; 2210-741X
• DOI: 10.1016/j.gcb.2010.06.010

Summary Objectives The most commonly used schedules are 5-FU in combination with CDDP with or without epirubicin (ECF) or docetaxel (TCF) in treatment of MGA patients (pts), independently of HER status. We evaluated the efficacy of FOLFIRI regimen in a large retrospective series of MGA pts. Methods Two hundred and twelve pts from 13 French centers were treated with at least one cycle of FOLFIRI (irinotecan 180 mg/m2 intravenous (i.v.) over 90 minutes on day 1 with folinic acid (FA) 400 mg/m2 i.v. over two hours followed by 5-FU 400 mg/m2 i.v. bolus then 5-FU 2400 mg/m2 continuous infusion over 46 hours on day 1, repeated every 14 days). Primary tumour sites were 120 (58%) stomach and 92 (42%) gastroesophageal junction. FOLFIRI was administered as first-line in 137 (65%) pts and as later-line in 75 (35%) pts for MGA. Results There was no difference between chemonaive and not chemonaive pts treated as first-line in terms of response rate 37% (95% CI: 25–50) vs 44% (95% CI: 21–69), median PFS, 6.7 (95% CI: 5.5–9.9) vs 5.3 months (95% CI: 3.6–6.9) ( P = 0.25), and OS, 13.1 (95% CI: 11.7–18.7) vs 8.8 months (95% CI: 7.3–15.6) ( P = 0.19), respectively. There was no difference between pts treated as second or later-line in terms of response rate 20% (95% CI: 8–39) vs 22% (95% CI: 6–48), median PFS, four months (95% CI: 2.8–5.4) vs 3.5 months (95% CI: 2.3–4.5) ( P = 0.56), and OS, 10.4 months (95% CI: 5.4–14.4) vs 5.3 months (95% CI: 3.5–11.3) ( P = 0.58), respectively. The global grade 3–4 toxicities were: diarrhea 11%, vomiting 9%, neutropenia 18%, febril neutropenia 4% (one toxic death). Conclusions This retrospective study confirms the activity and good tolerance of FOLFIRI regimen in MGA as first-line as well as later-line.